Yumi Nagatsuka, C. Nakashima, N. Kitayama, Yoshio Ishida, Kenji Kabashima, Atsushi Otsuka
{"title":"A case of unilateral epidermal nevi complicated by atopic dermatitis treated with dupilumab","authors":"Yumi Nagatsuka, C. Nakashima, N. Kitayama, Yoshio Ishida, Kenji Kabashima, Atsushi Otsuka","doi":"10.24294/ti.v8.i1.2773","DOIUrl":null,"url":null,"abstract":"Epidermal Nevus Syndrome (ENS) is a congenital disorder characterized by skin lesions called epidermal nevi. This condition typically appears at birth or in infancy. However, a case of adult‐onset epidermal nevi was reported in a 36‐year‐old male with a history of atopic dermatitis (AD) and skin abnormalities on the right side of his body. He had been using topical steroids for AD but eventually started dupilumab treatment at age 41. The treatment led to significant improvements in his skin condition, including a reduction in erythema and scaling. Laboratory tests also showed improvement in serum Immunoglobulin E (IgE) levels and other markers. We report with a literature review.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"185 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24294/ti.v8.i1.2773","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Epidermal Nevus Syndrome (ENS) is a congenital disorder characterized by skin lesions called epidermal nevi. This condition typically appears at birth or in infancy. However, a case of adult‐onset epidermal nevi was reported in a 36‐year‐old male with a history of atopic dermatitis (AD) and skin abnormalities on the right side of his body. He had been using topical steroids for AD but eventually started dupilumab treatment at age 41. The treatment led to significant improvements in his skin condition, including a reduction in erythema and scaling. Laboratory tests also showed improvement in serum Immunoglobulin E (IgE) levels and other markers. We report with a literature review.